Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Oncothyreon Inc (NASDAQ:ONTY)

1.03
Delayed Data
As of Feb 12
 +0.01 / +0.98%
Today’s Change
0.99
Today|||52-Week Range
4.69
-53.60%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$97.8M

Company Description

Oncothyreon, Inc. is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. Its current clinical-stage product candidates include ONT-380, an orally active and selective small-molecule HER2 inhibitor, and ONT-10, a therapeutic vaccine targeting the Mucin 1 peptide antigen. The company was founded on September 7, 2007 and is headquartered in Seattle, WA.

Contact Information

Oncothyreon, Inc.
2601 4th Avenue
Seattle Washington 98121
P:(206) 801-2100
Investor Relations:

Employees

Shareholders

Other institutional47.10%
Mutual fund holders18.70%
Individual stakeholders16.12%

Top Executives

Christopher S. HenneyChairman, President & Chief Executive Officer
Gary W. ChristiansonChief Operating Officer
Julia Marie EastlandCFO, Secretary & VP-Corporate Development
Scott Robert PetersonChief Scientific Officer
Diana F. HausmanChief Medical Officer